Adaptimmune Therapeutics (ADAP) Reports In-Line Q3 EPS

Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q3 EPS of ($0.01), in-line with the analyst estimate of ($0.01). Revenue for the quarter came in at $40.9 million versus the consensus estimate of $18.57 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.

You May Also Be Interested In

• Morgan Stanley continues to recommend exposure to the broadening theme
• Gorilla Technology raises Q2 2026 revenue outlook to $44M
• Stran hires casino sector veteran with $5M+ client portfolio